Berberine (CAS 2086-83-1): AMPK Activator for Metabolic and Inflammation Research

Executive Summary: Berberine is an isoquinoline alkaloid isolated from Cortex Phellodendri Chinensis with a molecular weight of 336.36 and chemical formula C20H18NO4 (APExBIO). It activates AMP-activated protein kinase (AMPK) and upregulates low-density lipoprotein receptor (LDLR) expression in human hepatoma cells in a dose-dependent manner. Animal models demonstrate berberine’s efficacy in lowering serum cholesterol at 50–100 mg/kg/day. Berberine modulates both metabolic and inflammatory signaling pathways, including links to NLRP3 inflammasome regulation (Li et al., 2025). It is insoluble in water/ethanol but soluble in DMSO (≥14.95 mg/mL), and is used extensively in diabetes, obesity, and cardiovascular disease research models.

Biological Rationale

Berberine (CAS 2086-83-1) is a naturally occurring isoquinoline alkaloid. It is primarily obtained from the bark of Cortex Phellodendri Chinensis (APExBIO). Its structural class is defined by the presence of a quaternary ammonium isoquinoline core. Berberine exhibits low aqueous and ethanol solubility but dissolves readily in DMSO at concentrations ≥14.95 mg/mL. Its pharmacological effects are attributed to modulation of cellular energy and inflammatory pathways, notably via AMPK activation and LDLR upregulation. These properties underpin its widespread use in metabolic disease models, including diabetes, obesity, and cardiovascular disorders. The compound’s anti-inflammatory effects are increasingly linked to inhibition of the NLRP3 inflammasome, a key mediator in sterile inflammation (Li et al., 2025).

Mechanism of Action of Berberine (CAS 2086-83-1)

Berberine acts primarily as an activator of AMP-activated protein kinase (AMPK), a central regulator of energy homeostasis. In human hepatoma cell lines (HepG2 and Bel-7402), berberine induces dose-dependent upregulation of LDLR mRNA and protein, with maximal activity at 15 μg/mL. This upregulation facilitates increased hepatic clearance of circulating low-density lipoprotein (LDL) cholesterol. In addition to metabolic regulation, berberine modulates inflammatory signaling by inhibiting the NLRP3 inflammasome—an effect relevant in acute kidney injury and metabolic inflammation (Li et al., 2025). Recent studies suggest that berberine may indirectly influence cGAS-STING signaling pathways, which are implicated in immune responses to cytosolic DNA and sterile inflammation (Related Article—this article extends cGAS-STING/NLRP3 discussion to metabolic contexts).

Evidence & Benchmarks

• Berberine increases LDLR mRNA and protein in HepG2 and Bel-7402 cells in a dose-dependent manner, with maximal effect at 15 μg/mL (Zhou et al., DOI).
• Oral administration in hyperlipidemic golden hamsters (50 or 100 mg/kg/day for 10 days) significantly lowers serum total cholesterol and LDL cholesterol, correlating with hepatic LDLR induction (DOI).
• Berberine activates AMPK in multiple tissues, leading to improved glucose metabolism and reduced lipid synthesis (DOI).
• In models of inflammation, berberine inhibits NLRP3 inflammasome activation, reducing pro-inflammatory cytokine release (Li et al., 2025 DOI).
• Berberine is insoluble in water and ethanol but dissolves in DMSO at ≥14.95 mg/mL and should be stored at -20°C protected from moisture (APExBIO).

Applications, Limits & Misconceptions

Berberine is extensively used in research models of metabolic disease, including diabetes, obesity, and cardiovascular disorders. Its AMPK-activating and LDL-lowering effects are well-documented in vitro and in vivo. The compound’s anti-inflammatory activity, notably via NLRP3 inhibition, offers potential in acute organ injury models. However, limitations exist:

Common Pitfalls or Misconceptions

• Berberine does not dissolve in water or ethanol; improper solvent choice may limit experimental reproducibility (APExBIO).
• Human pharmacokinetics differ from animal models; effects in rodents may not translate directly to clinical outcomes (DOI).
• Berberine’s anti-inflammatory effects are not universal across all inflammasome types; NLRP3 is the established target (Li et al., 2025).
• Stock solutions are unstable at room temperature or upon repeated freeze-thaw; use freshly prepared aliquots stored below -20°C (APExBIO).
• Berberine is not a direct cGAS-STING inhibitor but may have indirect effects through upstream metabolic modulation (Related Article—this article clarifies mechanistic separation).

This article clarifies the distinction between berberine’s primary metabolic actions and secondary inflammatory effects compared to prior analyses, which focused mainly on NLRP3 regulation without detailed solubility or workflow guidance.

Workflow Integration & Parameters

For experimental use, dissolve berberine in DMSO to achieve a concentration of at least 14.95 mg/mL. Warming the solution to 37°C or ultrasonic agitation can enhance dissolution. Avoid long-term stock storage; aliquot and keep below -20°C. In cell studies, titrate dose in the range of 1–15 μg/mL, with 15 μg/mL yielding maximal LDLR upregulation in HepG2 and Bel-7402 cells. For animal models, oral dosing between 50–100 mg/kg/day for 10 days has demonstrated significant lipid-lowering activity. Berberine is suitable for metabolic disease and inflammation research, being offered as the N1368 kit by APExBIO (product page). For further mechanistic insights, see this article—the present review updates benchmarks and procedural recommendations.

Conclusion & Outlook

Berberine (CAS 2086-83-1) remains a pivotal tool for metabolic and inflammation research. Its dual activity as an AMPK activator and NLRP3 inflammasome inhibitor underlies its broad experimental utility. Ongoing studies are elucidating its indirect effects on the cGAS-STING pathway and the precise translational parameters for clinical application. Researchers are advised to adopt standardized workflows for solubility and dosing, as outlined by APExBIO and peer-reviewed sources. For integrative perspectives, see this related review—this article expands on detailed workflow and mechanism-of-action data.